LitAlert ~~

    • Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A review and novel case with dual germline SMARCA4 and BRCA2 mutations.
    • Sanders BE, Wolsky R, Doughty ES, Wells KL, Ghosh D, Ku L, Pressey JG, Bitler BB, Brubaker LW.
    • Gynecol Oncol Rep. 2022 Oct 6 [eCollection 2022 Dec];44:101077. doi: 10.1016/j.gore.2022.101077.
    • Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
    • Jacot W, Lusque A, Vicier C, Mailliez A, de La Motte Rouge T, Cabel L, Levy C, Patsouris A, Desmoulins I, Uwer L, Thery JC, Robain M, Caron O, Tredan O, Filleron T, Frenel JS, Delaloge S.
    • Br J Cancer. 2022 Oct 7. doi: 10.1038/s41416-022-02003-1. Epub ahead of print.

    Identifier: NCT03275311: Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 (ESME-MBC). ( . Accessed 2022 Oct 7.)

    • Therapy related myeloid neoplasms following PARP inhibitors: real-life experience.
    • Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB.
    • Clin Cancer Res. 2022 Oct 6:CCR-22-1622. doi: 10.1158/1078-0432.CCR-22-1622. Epub ahead of print.
    • Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.
    • Marchetti C, Fagotti A, Scambia G.
    • J Clin Oncol. 2022 Oct 6:JCO2201585. doi: 10.1200/JCO.22.01585. Epub ahead of print.

    Letter, Reply:

    Reply to C. Marchetti et al.

    Original research:

    A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).

    • BRCA1/2 Variants Identified Through Tumor Genomic Profiling: Assessing Genetic Counseling Outcomes.
    • Harriman JW, Espinel WF, Vagher J, Gammon A.
    • JCO Precis Oncol. 2022;6:e210375. doi: 10.1200/PO.21.00375. Epub 2022 Oct 6.
    • Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer.
    • Huepenbecker SP, Wright JD, Downer MK, Incerti D, Luhn P, Dolado I, Bastiere-Truchot L, Lin YG, Chan JK, Meyer LA.
    • Obstet Gynecol. 2022 Oct 6. doi: 10.1097/AOG.0000000000004958. Epub ahead of print.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 1: Recent Updates in PARP Inhibitor Indications for Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 6.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 2: PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 6.
    • Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
    • Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D.
    • Cancer Treat Rev. 2022 Sep 28;111:102468. doi: 10.1016/j.ctrv.2022.102468. Epub ahead of print.